SCHOLAR ROCK HOLDING CORPORATION (SRRK) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 0.00 USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $0.00 | (m) | (m) |
| 2026-03-31 | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $0.00 | (m) | (m) |
| 2025-09-30 | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $33.19M | (m) | (m) |
| 2022-09-30 | (m) | $37.24M | (m) | (m) |
| 2022-06-30 | (m) | $42.71M | (m) | (m) |
| 2022-03-31 | (m) | $47.30M | (m) | (m) |
| 2021-12-31 | (m) | $18.82M | (m) | (m) |
| 2021-09-30 | (m) | $18.20M | (m) | (m) |
| 2021-06-30 | (m) | $15.78M | (m) | (m) |
| 2021-03-31 | (m) | $15.08M | (m) | (m) |
| 2020-12-31 | (m) | $15.40M | (m) | (m) |
| 2020-09-30 | (m) | $19.54M | (m) | (m) |
| 2020-06-30 | (m) | $21.28M | (m) | (m) |
| 2020-03-31 | (m) | $22.42M | (m) | (m) |
| 2019-12-31 | (m) | $20.49M | (m) | (m) |
| 2019-09-30 | (m) | $12.92M | (m) | (m) |
| 2019-06-30 | (m) | $8.14M | (m) | (m) |
| 2019-03-31 | (m) | $3.11M | (m) | (m) |
| 2018-12-31 | (m) | $0.00 | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |